3 completed, 1 recruiting. 4 Phase 1, 2 Phase 2.
By phase and status
Follow AL001: new trials by email Literature Review of AL001 trials Research Report on AL001
Trials (filtered) newest first · largest first
All 4 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder
AL001, Lithium carbonate - Bipolar I Disorder | Phase 1 / Phase 2 | Recruiting | Alzamend Neuro, Inc. | 20 | 2026-05-11 | 2026-07-28 |
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
AL001, Lithium Carbonate Capsule - Pharmacokinetics, Neurology | Phase 1 | Completed | Alzamend Neuro, Inc. | 15 | 2025-05-09 | 2026-07-29 |
Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
AL001, Placebo - Alzheimer's Disease, Healthy Non-elderly and Elderly Adults | Phase 1 / Phase 2 | Completed | Alzamend Neuro, Inc. | 65 | 2022-05-04 | 2025-05-14 |
A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation
AL001, Placebo - Healthy, Frontotemporal Dementia | Phase 1 | Completed | Alector Inc. | 64 | 2018-09-14 | 2020-07-27 |
Conditions studied
Alzheimer Disease (1) · Frontotemporal Dementia (1)
Sponsors
Alzamend Neuro, Inc. (3) · Alector Inc. (1)
Countries
United States (4) · Canada (2) · United Kingdom (1)
Top investigators
Eric Sicard, MD (1) · George Stoica (1)
Results publications
PMID 37322482